Rhumbline Advisers Agios Pharmaceuticals, Inc. Call Options Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AGIO
# of Institutions
227Shares Held
55.6MCall Options Held
275KPut Options Held
251K-
Farallon Capital Management LLC San Francisco, CA5.65MShares$334 Million1.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.5MShares$325 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$287 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.88MShares$229 Million2.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.78MShares$164 Million0.01% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $3.24B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...